Claims
- 1. An insertable or implantable medical device having distributed thereon an effective concentration of a biofilm-inhibiting compound that is sufficient to cause an effect on microbial biofilm in the microenvironment of a surface of said device, but which concentration is otherwise insufficient to cause a substantial therapeutic systemic effect in an organism in which said device is implanted or inserted.
- 2. An insertable or implantable medical device having reduced risk of causing infection after insertion or implantation comprising a device having distributed thereon between about 1 and 20 milliMolar surface concentration of a surface polysaccharide biofilm inhibiting compound.
- 3. A device according to claim 1 wherein said device is comprised of a polymer selected from the group consisting of silastic or other silicone-based material, polyethylene tecephtalate (PET), polyglacin, polydioxanone, chromic gut, nylon, silk, dacron, knitted dacron, velour dacron, bovine arterial graft, polyethylene (PE), polyvinyl chloride (PVC), silastic elastomer, silicone rubber, PMMA, latex, polypropylene (PP), titanium, cellulose, polyvinyl alcohol (PVA), poly-(hydroxyethyl methacrylate) (PHEMA), poly-(glycolic acid), poly (acrylonitrile) (PAN), floroethylene-co-hexafluoropropylene (FEP), teflon (PTFE), Co-Cr alloys, polyurethane, polyester, polytetrafluoroethylene, and biological polymers such as collagen.
- 4. A device according to claim 1 wherein said slime-inhibiting compound is a chelating agent.
- 5. A device according to claim 1 wherein said surface polysaccharide biofilm inhibiting compound is a NSAID.
- 6. A device according to claim 5 wherein said NSAID is selected from the group consisting of salicylic acid, acetylsalicylic acid (aspirin), bis-salicylate, benzyl-benzoic acid, diflunisal, fendosal, indomethacin, acemetacin, cinmetacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, isoxepac, ibuprofen, flurbiprofen, naproxen, ketoprofen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, mefenamic acid, flufenamic acid, meclofenamate, niflumic acid, tolfenamic acid, flunixin, clonixin, phenylbutazone, feprazone, apazone, trimethazone, mofebutazone, kebuzone, suxibuzone, piroxicam, isoxicam and tenoxicam.
- 7. A device according to claim 6 wherein said NSAID is salicylic acid or a salt thereof.
- 8. A device according to claim 6 wherein said NSAID is ibuprofen.
- 9. An insertable or implantable medical device having reduced risk of causing thrombophlebitis after insertion or implantation comprising a device having distributed thereon an effective amount of a NSAID insufficient to cause a substantial therapeutic systemic effect.
- 10. An insertable or implantable medical device having reduced risk of causing thrombophlebitis after insertion or implantation comprising a device having distributed thereon between about 1 and 20 milliMolar surface concentration of a NSAID.
- 11. A device according to claim 9 wherein said NSAID is selected from the group consisting of salicylic acid, acetylsalicylic acid (aspirin), bis-salicylate, benzyl-benzoic acid, diflunisal, fendosal, indomethacin, acemetacin, cinmetacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, isoxepac, ibuprofen, flurbiprofen, naproxen, ketoprofen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, mefenamic acid, flufenamic acid, meclofenamate, niflumic acid, tolfenamic acid, flunixin, clonixin, phenylbutazone, feprazone, apazone, trimethazone, mofebutazone, kebuzone, suxibuzone, piroxicam, isoxicam and tenoxicam.
- 12. A device according to claim 1 which further comprises a surface polysaccharide biofilm-inhibiting compound incorporated in the material used to make said device.
- 13. A device according to claim 2 wherein said device is comprised of a polymer selected from the group consisting of silastic or other silicone-based material, polyethylene tecephtalate (PET), polyglacin, polydioxanone, chromic gut, nylon, silk, dacron, knitted dacron, velour dacron, bovine arterial graft, polyethylene (PE), polyvinyl chloride (PVC), silastic elastomer, silicone rubber PMMA [poly-(methyl methacrylate)], latex, polypropylene (PP), titanium, cellulose, polyvinyl alcohol (PVA), poly-(hydroxyethyl methacrylate) (PHEMA), poly-(glycolic acid), poly (acrylonitrile) (PAN), floroethylene-co-hexafluoropropylene (FEP), teflon (PTFE), Co-Cr alloys, polyurethane, polyester, polytetrafluoroethylene, and biological polymers such as collagen.
- 14. A device according to claim 2 wherein said surface polysaccharide biofilm-inhibiting compound is a cheleting agent.
- 15. A device according to claim 2 wherein said surface polysaccharide biofilm-inhibiting compound is a NSAID.
- 16. A device according to claim 15 wherein said NSAID is selected from the group consisting of salicylic acid, acetylsalicylic acid (aspirin), bis-salicylate, benzyl-benzoic acid, difunisal, fendosal, indomethacin, acemethacin, cinmetacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, isoxepac, ibuprofen, flurbiprofen, naproxen, ketoprofen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, mefenamic acid, flufenamic acid, meclofenamate, niflumic acid, tolfenamic acid, flunixin, clonixin, phenylbutazone, feprazone, apazone, trimethazone, mofebutazone, kebuzone, suxibuzone, piroxicam, isoxicam and tenoxicam.
- 17. A device according to claim 16 wherein said NSAID is salicylic acid or a salt thereof.
- 18. A device according to claim 16 wherein said NSAID is ibuprofen.
- 19. A device according to claim 10 wherein said NSAID is selected from the group consisting of salicylic acid, acetylsalicylic acid (aspirin), bis-salicylate, benzyl-benzoic acid, diflunisal, fendosal, indomethacin, acemetacin, cinmetacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, isoxepac, ibuprofen, flurbiprofen, naproxen, ketoprofen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, mefenamic acid, flufenamic acid, meclofenamate, niflumic acid, tolfenamic acid, flunixin, clonixin, phenylbutazone, feprazone, apazone, trimethazone, mofebutazone, kebuzone, suxibuzone, piroxicam, isoxicam and tenoxicam.
- 20. A device according to claim 1 selected from the group consisting of a contact lens, an intraocular lens, a suture, a staple, a catheter, a heart valve, a graft, a prosthetic device and a dental area implant.
- 21. A device according to claim 2 selected from the group consisting of a contact lens, an intraocular lens, a suture, a staple, a catheter, a heart valve, a graft, a prosthetic device and a dental area implant.
Parent Case Info
This application is a continuation-in-part of application Ser. No. 07/802,891, filed on Dec. 6, 1991, now abandoned.
US Referenced Citations (7)
Non-Patent Literature Citations (3)
Entry |
D. G. Maki et al., Clinical Trial of a Novel Antiseptic Central Venous Catheter, Abstracts of the 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 176 (1991). |
C. J. Stephens et al. Randomized Double-Blind Trial Comparing the Risk of Peripheral Vein Thrombophlebitis (T) Between Chlorhexidine (CHA) Coated Catheters (C) with Uncoated Control, Abstracts of the 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 277 (1991). |
M. Tojo et al., Isolation and Characterization of a Capsular Polysaccharide Adhesin from Staphylococcus epidermidis, J. Infect. Dis. 157(4): 713-722 (1987). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
802891 |
Dec 1991 |
|